Mobile Site ›

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 80973 :
Hepatitis Be Antibody, Serum

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

During recovery from acute hepatitis B, the hepatitis Be antigen level declines and becomes undetectable and hepatitis Be antibody (anti-HBe) appears in the serum. Anti-HBe usually remains detectable for several years after recovery from acute infection.

 

In hepatitis B virus (HBV) carriers and in patients with chronic hepatitis B, positive anti-HBe results usually indicate inactivity of the virus and low infectivity of the patients. Positive anti-HBe results in the presence of detectable HBV DNA in serum indicate active viral replication.

 

See HBV Infection-Diagnostic Approach and Management Algorithm and Viral Hepatitis Serologic Profile in Special Instructions. Also see The Laboratory Approach to the Diagnosis and Monitoring of Hepatitis B Infection in Publications.

Useful For Suggests clinical disorders or settings where the test may be helpful

Determining infectivity of hepatitis B virus (HBV) carriers

 

Monitoring infection status of chronically HBV-infected patients

 

Monitoring serologic response of chronically HBV-infected patients who are receiving antiviral therapy

Interpretation Provides information to assist in interpretation of the test results

Absence of hepatitis Be (HBe) antigen with appearance of HBe antibody is consistent with loss of hepatitis (HBV) infectivity.

 

Although resolution of chronic HBV infection generally follows appearance of HBe antibody, the HBV carrier state may persist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Appearance of hepatitis Be antibody in serum does not completely rule out chronic hepatitis B carrier state or infectivity.

 

Performance characteristics of this assay have not been established in patients under the age of 2 or in populations of immunocompromised or immunosuppressed patients. This assay is not licensed by FDA for testing cord blood samples or screening donors of blood, plasma, human cell, or tissue products.

                                    

Performance characteristics have not been established for the following specimen characteristics:

-Grossly icteric (total bilirubin level of >20 mg/dL)

-Grossly lipemic (triglyceride level of >3,000 mg/dL)

-Grossly hemolyzed (hemoglobin level of >100 mg/dL)

-Containing particulate matter

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

See Viral Hepatitis Serologic Profiles in Special Instructions.

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Servoss JC, Friedman LS: Serologic and molecular diagnosis of hepatitis B virus. Clin Liver Dis 2004;8:267-281 

2. Badur S, Akgun A: Diagnosis of hepatitis B infections and monitoring of treatment. J Clin Virol 2001 Jun;21(3):229-237


Key